*Purpose: Statins are competitive inhibitors of HMG-CoA reductase, that catalyses the conversion of HMG-CoA to mevalonate, which is involved in the synthesis of cholesterol in humans and ergosterol in fungi. However, the effect of statin use on the risk of invasive aspergillosis (IA) in lung transplant recipients (LTRs) is not well documented.

*Methods: Consecutive LTRs from January 2010 to December 2014 were evaluated with one year follow-up from transplant. Proven or probable IA was diagnosed as per ISHLT criteria. A multivariate analysis of known risk factors of IA and statin use (minimum of two week before IA) was performed.

*Results: We identified 520 LTRs, 55% male, the median age 52 years old, the most common underlying disease was pulmonary fibrosis 130(25%). 48 (9.2%) LTRs developed IA in the first-year post-transplant. 53%(274/520) of the LTRs received statin. Atorvastatin was the most common used statin (70.4%). Out of the 48 LTRs only 12.5%( 6) had received statin prior the development of IA. The multivariate analysis of risk factors is shown in table 1. Statin use (OR 0.09;95%CI 0.04-0.24), double lung transplant (OR 0.38;95%CI 0.17-0.84) significantly decreased the risk of subsequent development of IA .

*Conclusions: Use of statin for a minimum of two weeks during first year of transplant was independently associated with decreased risk of IA in LTRs.

« Back to 2020 American Transplant Congress